🔴 MBX Biosciences is trading 5.9% down today after announcing a major executive leadership transition

MBX Biosciences is trading 5.9% down at $56.52 following the announcement of a major executive leadership transition effective immediately.

• The Board has appointed Executive Chairman Steve Hoerter as Chairman and Chief Executive Officer and confirmed John Smither as Chief Financial Officer, succeeding outgoing CEO Kent Hawryluk.
• Investors are reacting to the sudden top-level management shift within the clinical-stage biotech company, which was announced on July 13, 2026.